Compare MMI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMI | CMPX |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 926.7M |
| IPO Year | 2013 | 2020 |
| Metric | MMI | CMPX |
|---|---|---|
| Price | $25.39 | $5.27 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $28.00 | $14.43 |
| AVG Volume (30 Days) | 281.9K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 84.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $719,700,000.00 | N/A |
| Revenue This Year | $14.04 | N/A |
| Revenue Next Year | $11.35 | $830.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.43 | $1.33 |
| 52 Week High | $36.70 | $6.88 |
| Indicator | MMI | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 38.14 |
| Support Level | $24.89 | $4.78 |
| Resistance Level | $27.32 | $5.86 |
| Average True Range (ATR) | 0.79 | 0.30 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 8.99 | 24.22 |
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.